BLSM BlossomHill Therapeutics, Inc.
16.61USD-3.93%Mkt Cap: 527.95M $P/E: —1d ago
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clin…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update BlossomHill Therapeutics (NASDAQ:BLSM) shares rose 4. 4% in premarket trading after the company presented updated clinical data for investigational drug BH-30643 at the 2026 World Conference on Lung Cancer in Seoul, South Korea. | ||
 Insiders Are Betting Big on These 3 Healthcare Stocks Insiders are buying shares of Braveheart Bio, BlossomHill Therapeutics and Elanco, three health care stocks with differing risk profiles, analyst ratings, and pipeline catalysts ahead. | ||